Study Examines Clinical Trial Volunteers' Perceptions of Investigators' Financial Interests
Investigators' financial interests have little effect on potential clinical trial participants.
NY-April 3, 2008-The Journal of General Internal Medicine published a new study online that takes a look at how disclosing the financial interests of investigators affects the willingness of potential trial volunteers to participate. Generally, the research-compiled by Duke University School of Medicine, Johns Hopkins Berman Institute of Bioethics, Johns Hopkins School of Medicine, and Wake Forest School of Medicine and School of Law, and funded by the National Institutes of Health-showed that potential subjects' desires to volunteer were generally unaffected by learning about an investigator's financial interest, although some volunteers' levels of trust in the investigator was influenced upon the reveal of financial interests. To read more, visit www.springerlink.com/content/jn8914455w236040.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
